Skip to main content



Status: One Wales interim decision

Using the agreed starting and stopping criteria, rituximab can be made available within NHS Wales for the second-line treatment of pemphigus (excluding pemphigus vulgaris) and fourth-line treatment of pemphigoid disease in adults and children whose disease has not responded to previous treatments including steroids and steroid-sparing agents.

Rituximab for the treatment of moderate to severe pemphigus vulgaris was recommended for use by AWMSG in October 2022.

The risks and benefits of the off-label use of rituximab for this indication should be clearly stated and discussed with the patient to allow informed consent.

In August 2017 OWMAG recommended this treatment in NHS Wales, in July 2023 there was a review of the recommendation. OWMAG found nothing new that affects the original decision.

Next review: this decision will be reviewed again after three years or earlier if new evidence becomes available.

 One Wales Interim Decision (with start stop criteria and evidence review): Rituximab for pemphigus and pemphigoid disease in adults and children (OW10, 2023 review). (PDF, 59Kb)

Medicine details

Medicine name rituximab
Formulation Concentrate for solution for infusion
Reference number OW10

Treatment of adults and children with pemphigus (excluding pemphigus vulgaris) after failure of first-line treatments, including steroids and steroid-sparing treatments, and after failure of third-line treatments for pemphigoid disease, including steroids and steroid-sparing treatments

Company Various
BNF chapter Skin
Submission type One Wales
Status One Wales interim decision
Date of issue 01/08/2017
Date of last review July 2023
Follow AWTTC: